⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BDRX News
Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
globenewswire.com
BDRX
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
globenewswire.com
BDRX
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
accessnewswire.com
BDRX
GSK
PFE
NVS
COGT
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
globenewswire.com
BDRX
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
globenewswire.com
BDRX
Biodexa Announces Pricing of $10 Million Public Offering
globenewswire.com
BDRX
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
globenewswire.com
BDRX
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
globenewswire.com
BDRX
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
globenewswire.com
BDRX
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
globenewswire.com
BDRX